EPA Approves New MetaLarvTM S-PT Mosquito Growth Regulator Featuring Advanced Triple-Release Formulation Technology

Share Article

New Growth Regulator Prevents Maturation of Mosquito Larvae

The addition of MetaLarv S-PT to the VBC product portfolio demonstrates our commitment to working with our customers to develop custom solutions while constantly striving to improve public health in an environmentally sustainable way.

Valent BioSciences Corporation (VBC) announced that the U.S. Environmental Protection Agency (EPA) has granted registration approval for MetaLarvTM S-PT Mosquito Growth Regulator. MetaLarv S-PT contains the active ingredient S-methoprene, an insect juvenile hormone analog which prevents the development of mosquito larvae into the adult mosquito stage where certain species may be capable of transmitting harmful diseases such as West Nile virus, dengue fever, malaria, and encephalitis.

MetaLarv S-PT will allow mosquito control professionals the operational flexibility to apply mosquito larvicides to areas prior to flooding. Through its advanced Triple-Release Technology, MetaLarv S-PT can be applied up to 28 days prior to flooding and control adult emergence for up to 42 days after flooding, regardless of dry-down and re-flood conditions.

In addition to its ability to provide residual control of floodwater mosquitoes, MetaLarv S-PT’s unique pellet formulation and spherical shape is virtually dust free and allows for more effective low-rate applications, improved aerial application swaths, and greater point-source coverage. These features improve upon current pellet offerings by reducing operational costs, improving worker cleanliness and providing greater peace of mind.

“The addition of MetaLarv S-PT to the VBC product portfolio demonstrates our commitment to working with our customers to develop custom solutions while constantly striving to improve public health in an environmentally sustainable way,” said Ernest Dankwa, Senior Global Business Manager for VBC’s Public Health and Forestry Business Unit. “Our goal is to provide a continuum of solutions based on specific habitats that are attractive to mosquito breeding.”

MetaLarv S-PT joins VBC’s biorational mosquito larvicides VectoBac®, VectoMax®, VectoLex®, and Teknar® Biological Insecticides to provide the public health industry’s most comprehensive range of target-specific, biorational larvicides for mosquito abatement professionals and health care officials around the globe.

For more information about MetaLarv S-PT or any other target-specific, biorational mosquito larvicides, contact ernest.dankwa(at)valentbiosciences(dot)com.

VBC is a subsidiary of Tokyo-based Sumitomo Chemical Company, Limited. Sumitomo is the only company in the world with a strategic focus in both traditional and biorational agricultural products.

About Valent BioSciences Corporation: Valent BioSciences Corporation is headquartered in Libertyville, Illinois, and is the worldwide leader in the development, manufacturing and commercialization of biorational products, with sales in over 90 countries around the world. Products include microbial pesticides and plant growth regulators used in agricultural and forestry markets, microbial-based products for use in public health markets, and insecticides used in household consumer markets. Valent BioSciences distributes products direct and through Sumitomo Chemical regional companies around the world and is an ISO 9001:2008 Certified Company. For additional information, visit the company’s website at http://www.valentbiosciences.com.

About Sumitomo Chemical Company, Limited: Sumitomo Chemical Company is one of Japan’s leading chemical companies, offering a diverse range of products globally in the fields of basic chemicals, petrochemicals, fine chemicals, IT-related chemicals and materials, agricultural chemicals, and pharmaceuticals. The company’s consolidated net sales for fiscal 2009 were US$17.4 billion (JPY1.62 trillion). For additional information, visit the company’s website at http://www.sumitomo-chem.co.jp/english/.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Barbara Wendling
Visit website

Media